Marina Nunez, M.D., Ph.D.
Associate Professor, Infectious Diseases
HIV Infections; Antiretroviral Therapy, Highly Active; Hepatitis C; Hepatitis C, Chronic; HIV
Academic: 336-716-2700 | Department: 336-716-2700
Use of electronic health record clinical decision support tool for HCV birth cohort screening [letter]. Fitch DN, Dharod A, Campos CL, Nunez M.. J Viral Hepat. 2017;24(11):1076.
Use of an EHR clinical decision support tool for HCV birth cohort screening: a single center experience [abstract]. Fitch DN, Dharod A, Campos C, Nunez M.. Hepatology. 2016;63(1 Suppl):403A.
Outcomes in HIV-HBV-coinfected patients in the tenofovir era are greatly affected by immune suppression. Huang AJ, Nunez M.. J Int Assoc Provid AIDS Care. 2015;14(4):360-368.
Drug-induced liver injury in hospitalized HIV patients: high incidence and association with drugs for tuberculosis. Gomes Martins de Moura Tomich L, Nunez M, Mendes-Correa MC.. Ann Hepatol. 2015;14(6):888-894.
Hepatic peroxisome proliferator-activated receptor gamma and alpha-mRNA expression in HCV-infected adults is decreased by HIV co-infection and is also affected by ethnicity. Shores NJ, Mendes-Correa MC, Maida I, Turner J, High KP, Babudieri S, Nunez M.. Clinics (Sao Paulo). 2015;70(12):790-796.
Sorafenib therapy in HIV-infected patients with hepatocellular carcinoma (HCC) [abstract]. Kikuchi L, Citti CC, Chen TY, Platt HL, Kaplan DE, Vetura-Cots M, Jain MK, Vispo E, Daruich J, Nunez M, Barreiro P, Minguez B, Aytaman A, Rimland D, Brau N.. Hepatology. 2015;62(Suppl 1):430A.
Transient hepatitis B surface antigenemia after hepatitis B virus vaccine in an HIV-infected patient [letter]. Barbour S, Bachmann L, Nunez M.. AIDS Res Hum Retroviruses. 2013;29(4):639-640.
Viral hepatitis and HIV: update and management. Nunez M, Mendes-Correa MC.. Antivir Ther. 2013;18(3 Pt B):451-458.
Outcome of HCV genotype 1 treatment in HIV-coinfected patients with chronic kidney disease. Oppenheimer AP, Johnson J, Nunez M.. J Int Assoc Provid AIDS Care. 2013;12(1):55-57.
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Nunez M, Nuesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R.. PLoS One. 2013;8(7):e68152.
JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Divers J, Nunez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI.. Kidney Int. 2013;84(6):1207-1213.
Poor correlation between ALT normalization and virological response to hepatitis C treatment [abstract]. Nguyen V, Nunez M.. Am J Gastroenterol. 2013;108(Suppl 1):S149.
STARTVerso 4 Phase III trial of faldaprevir plus peg interferon alfa-2a and ribavirin (PR) in patients with HIV and HCV genotype 1 coinfection: end of treatment response [abstract]. Rockstroh JK, Nelson M, Soriano V, Arasteh K, Guardiola JM, Bhagani S, Mallolas J, Tural C, Puoti M, Ingliz P, Battegay M, Jain MK, Nunez M, Marks KM, Kort JJ, Stern JO, Vinisko R, Manero M, Dieterich DT.. Hepatology. 2013;58(Suppl 1):741A-742A.
MESIAH score, BCLC, and other staging models as predictors of survival of hepatocellular carcinoma in HIV-infected patients [abstract]. Jain MK, Kikuchi LO, Minguez B, Ventura M, Vispo E, Chen TY, Badshah MB, Page EE, Taylor LE, Marks KM, Nunez M, Hernandez MD, Jalali Z, Palys E, Qazi N, Harris M, Fox RK, Aytaman A, Aberg J, Brau N.. Hepatology. 2013;58(Suppl 1):1248A-49A.
Liver toxicity of antiretroviral drugs. Jones M, Nunez M.. Semin Liver Dis. 2012;32(2):167-176.
Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Freedman BI, Langefeld CD, Turner J, Nunez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J.. Kidney Int. 2012;82(7):805-811.
Higher risk of severe drug-induced liver injury among Hispanic HIV-infected patients after initiation of highly active antiretroviral therapy. Lamar ZS, Nunez M.. J Int Assoc Physicians AIDS Care (Chic Ill). 2011;10(3):183-186.
Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use. Connoy A, Turner J, Nunez M.. AIDS Res Hum Retroviruses. 2011;27(7):719-725.
HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management. Jones M, Nunez M.. Curr Opin HIV AIDS. 2011;6(6):546-552.
Hepatic PPAR gamma expression is further impaired in HCV-infected subjects with HIV-co-infection [abstract]. Shores N, Mendes-Correa MC, Maida I, Turner J, Uip DE, High K, Nunez M.. Hepatology. 2011;54(Suppl 1):1331A.
Gene-gene and gene-environment interactions in HIV-associated nephropathy: a focus on the MYH9 nephropathy susceptibility gene. Nunez M, Saran AM, Freedman BI.. Adv Chronic Kidney Dis. 2010;17(1):44-51.
Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients. Shores NJ, Maida I, Perez-Saleme L, Nunez M.. J Int Assoc Physicians AIDS Care (Chic Ill). 2010;9(1):15-19.
Routine hepatitis B virus DNA testing in human immunodeficiency virus-infected patients with positive hepatitis B core antibody but negative hepatitis B surface antigen is not justified by current evidence [letter]. Nunez M.. Hepatology. 2010;51(3):1087-1088.
Improved survival of hepatocellular carcinoma (HCC) in HIV-infected patients with undetectalbe HIV RNA [abstract]. Brau N, Kikuchi L, Nunez M, Barreiro P, Nelson M, Bini EJ, Kristen M, Fox R, Sherman M, Puoti M.. J Hepatol. 2010;52(Suppl 1):S219.
Impact of screening for hepatocellular carcinoma (HCC) in HIV/HCV-coinfected patients on staging, therapy and survival [abstract]. Kikuchi L, Nunez M, Barreiro P, Nelson M, Vispo ME, Page E, Puoti M, Fox R, Sherman M, Carrilho F, et al.. J Hepatol. 2010;52(Suppl 1):S412.
Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Nunez M.. Hepatology. 2010;52(3):1143-1155.
Management of HIV and hepatitis virus coinfection. Mendes-Correa M, Nunez M.. Expert Opin Pharmacother. 2010;11(15):2497-2516.
Age and hepatocellular carcinoma in HIV-infected patients [abstract]. Kaplan DE, Daruich J, Jalali Z, Rafiullah, Nunez M, Vogel M, Vispo E, Barreiro P, Rockstroh JK, Mauss S, et al.. Hepatology. 2010;52(4 Suppl):1174-5A.
Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. Lee T, Nunez M.. HIV Clin Trials. 2009;10(3):153-159.
First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. Townsend D, Troya J, Maida I, Perez-Saleme L, Satta G, Wilkin A, Barreiro P, Pegram PS, Soriano V, Nunez M, et al.. J Int Assoc Physicians AIDS Care (Chic Ill). 2009;8(5):314-317.
Effect of HIV on levels of serum markers of liver inflammation and fibrosis in hepatitis C virus co-infection [abstract]. Nunez M, Beltz A, High K.. Hepatology. 2009;50(4 Suppl):923A-924A.
Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. Maida I, Rios MJ, Perez-Saleme L, Ramos B, Soriano V, Pegram PS, Mura MS, Sanchez-Margalet V, Wilkin A, Nunez M, et al.. AIDS Res Hum Retroviruses. 2008;24(5):679-683.
Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. Yacisin K, Maida I, Rios MJ, Soriano V, Nunez M.. AIDS Res Hum Retroviruses. 2008;24(7):935-940.
Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. Shores NJ, Maida I, Soriano V, Nunez M.. J Hepatol. 2008;49(3):323-328.
Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions [editorial]. Soriano V, Rivas P, Nunez M.. Clin Infect Dis. 2008;47(11):1486-1489.
Response to Cicconi et al. 'Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?' [letter]. Nunez M.. AIDS. 2007;21(12):1660.
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO Trial. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, De Los Santos I, San Joaquin I, et al.. AIDS Res Hum Retroviruses. 2007;23(8):972-982.
Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients [editorial]. Nunez M, Soriano V, Lopez M, Ballesteros C, Cascajero A, Gonzalez-Lahoz J, Benito JM.. Clin Infect Dis. 2006;43(9):1209-1212.
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. Nunez M, Ramos B, Diaz-Pollan B, Camino N, Martin-Carbonero L, Barreriro P, Gonzalez-Lahoz J, Soriano V.. AIDS Res Hum Retroviruses. 2006;22(9):842-848.
Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martin-Carbonero L, Barreiro P, Rivas P, Gonzalez-Lahoz J, Nunez M.. HIV Clin Trials. 2006;7(5):246-250.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.